TLR9 Signaling Activation at Different Stages in Colorectal Cancer and NF-kappaB Expression

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Oct 2

PMID 30271180

Citations 18

Authors

Caixia Gao

Tiankui Qiao

Bin Zhang

Sujuan Yuan

Xibing Zhuang

Youjun Luo

Affiliations

Soon will be listed here.

Abstract

Background: The relationship of inflammation and tumor is becoming more and more important in the study on the pathogenesis of colorectal cancer. The role of TLR9-mediated immune inflammation reaction in the process is not currently clear. The purpose of the study was to discuss the correlation of TLR9 signal activation with tumor progression by detecting the expression of TLR9 and its downstream molecule NF-kappaB in colorectal cancer tissues at different stages.

Methods: TLR9 expression in colorectal cancer tissues was detected by immunohistochemical streptavidin-perosidase method and Western blot.

Results: The result showed that the high expression of TLR9 was correlated with tumor poorly differentiation, invasion and liver metastasis, the abnomal increasing levels of CEA in blood. With the signal activation, the levels of TLR9 protein raised more in advanced colorectal cancer than in early colorectal cancer. Afterward, we found that the activation of specific expression of TLR9 signal was related to histologic origin. TLR9-C expression displayed in both advanced cancer and para-carcinoma tissues, and TLR9-R protein was predominat in partial sigmoid and rectal cancer tissues. With the differential expression of TLR9, the levels of its downstream molecule NF-kappaB protein increased in colon cancer tissues and decreased in rectal cancer tissues.

Conclusion: The results confirmed that TLR9 signaling activation participated in the clinical process of colorectal cancer and influenced NF-kappaB expression.

Citing Articles

Understanding the Role of Toll-Like Receptors 9 in Breast Cancer.

Al-Alem U, Al-Saruri A, Bamahros H, Mahmoud A, Sible E, Hasan U Cancers (Basel). 2024; 16(15).

PMID: 39123407 PMC: 11311448. DOI: 10.3390/cancers16152679.

Impact of and gene polymorphisms on prognosis and survival of patients with oral squamous cell carcinoma.

Obrenovic M, Supic G, Miyabe S, Mladenovic I, Kozomara R, Jovic S Biomol Biomed. 2024; 24(6):1682-1691.

PMID: 38850110 PMC: 11496855. DOI: 10.17305/bb.2024.10550.

Toll-like receptors in health and disease.

Wang K, Huang H, Zhan Q, Ding H, Li Y MedComm (2020). 2024; 5(5):e549.

PMID: 38685971 PMC: 11057423. DOI: 10.1002/mco2.549.

Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.

Li H, Wang S, Yang Z, Meng X, Niu M Bioact Mater. 2024; 36:376-412.

PMID: 38544737 PMC: 10965438. DOI: 10.1016/j.bioactmat.2024.03.003.

Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives.

Mukherjee S, Patra R, Behzadi P, Masotti A, Paolini A, Sarshar M Front Immunol. 2023; 14:1244345.

PMID: 37822929 PMC: 10562563. DOI: 10.3389/fimmu.2023.1244345.

References

Eiro N, Gonzalez L, Gonzalez L, Andicoechea A, Fernandez-Diaz M, Altadill A . Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol. 2012; 32(4):848-54. DOI: 10.1007/s10875-012-9666-3. View

Xu L, Wang C, Wen Z, Zhou Y, Liu Z, Liang Y . CpG oligodeoxynucleotides enhance the efficacy of adoptive cell transfer using tumor infiltrating lymphocytes by modifying the Th1 polarization and local infiltration of Th17 cells. Clin Dev Immunol. 2010; 2010:410893. PMC: 2963116. DOI: 10.1155/2010/410893. View

Meng Y, Kujas M, Marie Y, Paris S, Thillet J, Delattre J . Expression of TLR9 within human glioblastoma. J Neurooncol. 2008; 88(1):19-25. DOI: 10.1007/s11060-008-9536-2. View

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H . A Toll-like receptor recognizes bacterial DNA. Nature. 2000; 408(6813):740-5. DOI: 10.1038/35047123. View

Takeda K, Kaisho T, Akira S . Toll-like receptors. Annu Rev Immunol. 2003; 21:335-76. DOI: 10.1146/annurev.immunol.21.120601.141126. View

Zarember K, Godowski P . Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002; 168(2):554-61. DOI: 10.4049/jimmunol.168.2.554. View

Chang Y, Wu M, Lin J, Chen C . Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol. 2005; 175(12):8242-52. DOI: 10.4049/jimmunol.175.12.8242. View

Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y . TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res. 2009; 15(4):623-30. DOI: 10.1007/s12253-009-9162-0. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

10.

Ronkainen H, Hirvikoski P, Kauppila S, Vuopala K, Paavonen T, Selander K . Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res. 2011; 30:84. PMC: 3182949. DOI: 10.1186/1756-9966-30-84. View

11.

Chen R, Alvero A, Silasi D, Steffensen K, Mor G . Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. Oncogene. 2008; 27(2):225-33. DOI: 10.1038/sj.onc.1210907. View

12.

Sinha S, Cameron J, Brooks J, Leifer C . Complex Negative Regulation of TLR9 by Multiple Proteolytic Cleavage Events. J Immunol. 2016; 197(4):1343-52. PMC: 4976034. DOI: 10.4049/jimmunol.1502357. View

13.

Inoue J, Gohda J, Akiyama T, Semba K . NF-kappaB activation in development and progression of cancer. Cancer Sci. 2007; 98(3):268-74. PMC: 11158158. DOI: 10.1111/j.1349-7006.2007.00389.x. View

14.

Krieg A, Yi A, Matson S, Waldschmidt T, Bishop G, Teasdale R . CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995; 374(6522):546-9. DOI: 10.1038/374546a0. View

15.

Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez L, del Casar J, Lamelas M . Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010; 10:665. PMC: 3009680. DOI: 10.1186/1471-2407-10-665. View

16.

Vaisanen M, Vaisanen T, Jukkola-Vuorinen A, Vuopala K, Desmond R, Selander K . Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate. 2010; 70(8):817-24. DOI: 10.1002/pros.21115. View

17.

Merrell M, Ilvesaro J, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E . Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006; 4(7):437-47. DOI: 10.1158/1541-7786.MCR-06-0007. View

18.

Droemann D, Albrecht D, Gerdes J, Ulmer A, Branscheid D, Vollmer E . Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res. 2005; 6:1. PMC: 544843. DOI: 10.1186/1465-9921-6-1. View

19.

Lee S, Kang D, Ra E, Lee T, Ploegh H, Park B . Negative self-regulation of TLR9 signaling by its N-terminal proteolytic cleavage product. J Immunol. 2014; 193(7):3726-35. PMC: 4285150. DOI: 10.4049/jimmunol.1400210. View

20.

Chen K, Huang J, Gong W, Iribarren P, Dunlop N, Wang J . Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol. 2007; 7(10):1271-85. DOI: 10.1016/j.intimp.2007.05.016. View